Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocetinostat and Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma
NCT02429375Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2015
- Primary completion
- Feb 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mocetinostat in Hodgkin lymphoma (HL), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2015; status: completed.
02
Drugs
mocetinostat
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02429375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429375.